Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
660
mi
from 43215
Jackson, MS
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
University of Mississippi Medical Center
660
mi
from 43215
Jackson, MS
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
682
mi
from 43215
Omaha, NE
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
Children's Hospital and Medical Center of Omaha
682
mi
from 43215
Omaha, NE
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
682
mi
from 43215
Omaha, NE
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
Univ of Nebraska Med Ctr
682
mi
from 43215
Omaha, NE
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
476
mi
from 43215
Hackensack, NJ
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
Hackensack University Medical Center
476
mi
from 43215
Hackensack, NJ
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
453
mi
from 43215
New Brunswick, NJ
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
Saint Peter's University Hospital
453
mi
from 43215
New Brunswick, NJ
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
453
mi
from 43215
New Brunswick, NJ
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
UMDNJ-Robert Wood Johnson University Hospital
453
mi
from 43215
New Brunswick, NJ
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
477
mi
from 43215
New York, NY
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
Columbia University Medical Center
477
mi
from 43215
New York, NY
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
480
mi
from 43215
New York, NY
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
Memorial Sloan Kettering Cancer Center
480
mi
from 43215
New York, NY
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
354
mi
from 43215
Rochester, NY
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
University of Rochester
354
mi
from 43215
Rochester, NY
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
417
mi
from 43215
Syracuse, NY
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
State University of New York Upstate Medical University
417
mi
from 43215
Syracuse, NY
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
491
mi
from 43215
Valhalla, NY
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
Ny Cancer%
491
mi
from 43215
Valhalla, NY
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
353
mi
from 43215
Chapel Hill, NC
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
Univ of North Carolina
353
mi
from 43215
Chapel Hill, NC
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
349
mi
from 43215
Charlotte, NC
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
Carolinas Medical Center
349
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
352
mi
from 43215
Durham, NC
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
Duke Univ Med Ctr
352
mi
from 43215
Durham, NC
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
837
mi
from 43215
Fargo, ND
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
Sanford Medical Center-Fargo
837
mi
from 43215
Fargo, ND
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
110
mi
from 43215
Akron, OH
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
Children's Hospital Medical Center of Akron
110
mi
from 43215
Akron, OH
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
138
mi
from 43215
Cleveland, OH
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
Cleveland Clinic Foundation
138
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
841
mi
from 43215
Oklahoma City, OK
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
University of Oklahoma Health Sciences Center
841
mi
from 43215
Oklahoma City, OK
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
2026
mi
from 43215
Portland, OR
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
Legacy Emanuel Hospital and Health Center
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
2026
mi
from 43215
Portland, OR
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
Oregon Health and Science University
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
337
mi
from 43215
Hershey, PA
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
Penn State Hershey Children's Hospital
337
mi
from 43215
Hershey, PA
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
416
mi
from 43215
Philadelphia, PA
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
Saint Christopher's Hospital for Children
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
619
mi
from 43215
Providence, RI
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
Rhode Island Hospital
619
mi
from 43215
Providence, RI
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
422
mi
from 43215
Columbia, SC
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
Palmetto Health Richland
422
mi
from 43215
Columbia, SC
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
334
mi
from 43215
Nashville, TN
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
Vanderbilt-Ingram Cancer Center
334
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
910
mi
from 43215
Dallas, TX
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
University of Texas Southwestern Medical Center
910
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
938
mi
from 43215
Fort Worth, TX
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
Cook Children's Medical Center
938
mi
from 43215
Fort Worth, TX
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
991
mi
from 43215
Houston, TX
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
Baylor College of Medicine
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
1514
mi
from 43215
Salt Lake City, UT
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
Primary Children's Hospital
1514
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
590
mi
from 43215
Burlington, VT
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
University of Vermont
590
mi
from 43215
Burlington, VT
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
2005
mi
from 43215
Seattle, WA
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
Seattle Children's Hospital
2005
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
2012
mi
from 43215
Tacoma, WA
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
Mary Bridge Children's Hospital and Health Center
2012
mi
from 43215
Tacoma, WA
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
330
mi
from 43215
Milwaukee, WI
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
Midwest Children's Cancer Center
330
mi
from 43215
Milwaukee, WI
Click here to add this to my saved trials
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated:  3/16/2016
11247
mi
from 43215
Perth,
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years
Status: Enrolling
Updated: 3/16/2016
Princess Margaret Hospital for Children
11247
mi
from 43215
Perth,
Click here to add this to my saved trials
Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
A Phase II Trial of MRD (Melphalan, Lenalidomide and Dexamethasone) for Patients With AL Amyloidosis
Status: Enrolling
Updated:  3/16/2016
643
mi
from 43215
Boston, MA
Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
A Phase II Trial of MRD (Melphalan, Lenalidomide and Dexamethasone) for Patients With AL Amyloidosis
Status: Enrolling
Updated: 3/16/2016
Boston University Cancer Research Center
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
Vorinostat (SAHA) and Lenalidomide After Autologous Transplant for Patients With Multiple Myeloma
Status: Enrolling
Updated:  3/16/2016
2
mi
from 43215
Columbus, OH
Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
Vorinostat (SAHA) and Lenalidomide After Autologous Transplant for Patients With Multiple Myeloma
Status: Enrolling
Updated: 3/16/2016
Ohio State University
2
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
492
mi
from 43215
Birmingham, AL
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
University of Alabama
492
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
1643
mi
from 43215
Scottsdale, AZ
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
Mayo-Scottsdale
1643
mi
from 43215
Scottsdale, AZ
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
624
mi
from 43215
Little Rock, AR
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
University of Arkansas for Medical Sciences
624
mi
from 43215
Little Rock, AR
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
1970
mi
from 43215
Los Angeles, CA
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
USC Norris Cancer Center
1970
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
2100
mi
from 43215
Stanford, CA
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
Stanford Medical Center
2100
mi
from 43215
Stanford, CA
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
823
mi
from 43215
Tampa, FL
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
Moffitt Cancer Center
823
mi
from 43215
Tampa, FL
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
432
mi
from 43215
Atlanta, GA
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
Emory University School of Medicine
432
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
496
mi
from 43215
Macon, GA
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
ACORN-Central Georgia Hematology/Oncology
496
mi
from 43215
Macon, GA
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
274
mi
from 43215
Chicago, IL
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
Northwestern University
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
270
mi
from 43215
Chicago, IL
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
University of Chicago
270
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
163
mi
from 43215
Beech Grove, IN
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
St. Francis Cancer Care Services
163
mi
from 43215
Beech Grove, IN
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
167
mi
from 43215
Indianapolis, IN
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
Indiana Cancer Pavillion
167
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
460
mi
from 43215
Iowa City, IA
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
University of Iowa Hospitals and Clinics
460
mi
from 43215
Iowa City, IA
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
789
mi
from 43215
Shreveport, LA
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
LSU Shreveport
789
mi
from 43215
Shreveport, LA
Click here to add this to my saved trials